Related Experiment Video
Updated: Jul 5, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
Yannick Arlot-Bonnemains1, Enke Baldini, Benedicte Martin
1CNRS-UMR 6061 Génétique et Développement, IFR 140 GFAS, Faculté de Médecine, Université Rennes 1, 35043 Rennes Cedex, France.
Abstract:
Anaplastic thyroid cancers (ATC) are aggressive tumors, which exhibit cell cycle misregulations leading to uncontrolled cellular proliferation and genomic instability. They fail to respond to chemotherapeutic agents and radiation therapy, and most patients die within a few months of diagnosis. In the present study, we evaluated the in vitro effects on ATC cells of VX-680, an inhibitor of the Aurora serine/threonine kinases involved in the regulation of multiple aspects of chromosome segregation and cytokinesis. The effects of VX-680 on proliferation, apoptosis, soft agar colony formation, cell cycle, and ploidy were tested on the ATC-derived cell lines CAL-62, 8305C, 8505C, and BHT-101. Treatment of the different ATC cells with VX-680 inhibited proliferation in a time- and dose-dependent manner, with the IC50 between 25 and 150 nM. The VX-680 significantly impaired the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity showed that VX-680 induced apoptosis in the different cell lines. CAL-62 cells exposed for 12 h to VX-680 showed an accumulation of cells with > or =4N DNA content. Time-lapse analysis demonstrated that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation was abrogated following VX-680 treatment. In conclusion, our data demonstrated that VX-680 is effective in reducing cell growth of different ATC-derived cell lines and warrant further investigation to exploit its potential therapeutic value for ATC treatment.
Insights
VX-680, an Aurora kinase inhibitor, effectively reduces anaplastic thyroid cancer (ATC) cell growth by inhibiting proliferation and inducing apoptosis. This study highlights VX-680
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Anaplastic thyroid cancer (ATC) is an aggressive malignancy with poor prognosis.
- ATC cells exhibit cell cycle dysregulation, uncontrolled proliferation, and genomic instability.
- Current treatments for ATC have limited efficacy.
Purpose of the Study:
- To evaluate the in vitro efficacy of VX-680, an Aurora kinase inhibitor, against anaplastic thyroid cancer cells.
- To assess the effects of VX-680 on ATC cell proliferation, apoptosis, colony formation, cell cycle, and ploidy.
Main Methods:
- VX-680 treatment of ATC cell lines (CAL-62, 8305C, 8505C, BHT-101).
- Assays for proliferation, apoptosis (caspase-3 activity), soft agar colony formation, cell cycle analysis, and ploidy.
- Time-lapse microscopy and histone H3 phosphorylation analysis.
Main Results:
- VX-680 inhibited ATC cell proliferation in a dose- and time-dependent manner (IC50: 25-150 nM).
- VX-680 significantly reduced soft agar colony formation and induced apoptosis.
- VX-680 treatment led to polyploidy (cells with >4N DNA content) and aberrant cell division, abrogating histone H3 phosphorylation.
Conclusions:
- VX-680 demonstrates significant in vitro anti-cancer activity against multiple ATC cell lines.
- VX-680's mechanism involves cell cycle disruption, leading to proliferation inhibition and apoptosis.
- VX-680 shows therapeutic potential for anaplastic thyroid cancer treatment, warranting further investigation.
More Related Videos
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023